Cipla down 8% in 5 days, nears 52-week low on warning letter for Goa plant

The Company said it remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Shares of Cipla were trading lower for the fifth straight day, down 3 per cent at Rs 409 on the BSE on Thursday. The company on Wednesday said it received a warning letter from United States Food and Drug Administration (USFDA) for its Goa manufacturing facility.

The stock of the pharmaceutical company was trading close to its 52-week low of Rs 390 touched on October 11, 2019. In the past five trading days, Cipla slipped 8.5 per cent, as compared to a 4 per cent decline in the benchmark S&P BSE Sensex and 3 per cent fall in the